Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 40 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $22.727 million which beat the analyst consensus estimate of $21.450 million by 5.95 percent. This is a 11.13 percent increase over sales of $20.450 million the same period last year.